GLPwatch
Papers (12034)
Page 130 of 201, ranked by citation count.
- A Peptide in a Pill - Oral Semaglutide in the Management of Type 2 Diabetes.
- The safety of albiglutide for the treatment of type 2 diabetes.
- Incretin mimetics for weight loss forgive nonadherence.
- Tirzepatide for the treatment of heart failure in Type 2 diabetes mellitus: (SUR)PASS, or not?
- Efficacy of liraglutide on glycemic endpoints in people of Western European and South Asian descent with T2DM using multiple daily insulin injections: results of the MAGNA VICTORIA studies.
- Safety and effectiveness of dulaglutide 0.75 mg in Japanese patients with type 2 diabetes in real-world clinical practice: 36 month post-marketing observational study.
- Engineering a protease-based and site-specific PEGylation-based strategy for the controlled release of exenatide.
- Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) According to Baseline HbA1c and BMI.
- Potential Role of Hypothalamic and Plasma Ghrelin in the Feeding Behavior of Obese Type 2 Diabetic Rats with Intraventricular Glucagon-Like Peptide-1 Receptor Agonist Intervention.
- Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy.
- Effect of liraglutide on the dysglycemia, inflammation, and gut microbiota in prediabetic KKay mice.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Global Rise of Compounded Weight-Loss Medicines: A Worrisome Trend.
- Evaluating Weight Loss Associated with Bariatric Surgery After Liraglutide Use: A Matched Population-Level Retrospective Cohort Study.
- Raised intracranial pressure alters cortical vascular function and cephalic allodynia.
- Characteristics of WBN/Kob diabetic fatty rats supplemented with a fructose-rich diet as a metabolic syndrome model: response to a GLP-1 receptor agonist.
- Reversible bilateral central scotoma under scotopic conditions associated with oral semaglutide.
- Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review.
- Targeting the LPI/GPR55 Axis in MAFLD and MASH: Novel Insights, Therapeutic Strategies and Future Directions.
- Facilitated structure verification of the biopharmaceutical peptide exenatide by 2D heteronuclear NMR maps.
- Comparative Efficacy and Safety of Oral Semaglutide in Asians and Non-Asians Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
- Comparison of the renal outcomes of novel antidiabetic agents in patients with type 2 diabetes with chronic kidney disease: A systematic review and network meta-analysis of randomized controlled trials.
- Endocannabinoid-related molecules predict the metabolic efficacy of GLP-1 receptor agonism in humans with obesity.
- Safety and Efficacy of Liraglutide and Semaglutide in Kidney Transplant Recipients.
- Effect of iGlarLixi on continuous glucose monitoring-measured time in range in insulin-naive adults with suboptimally controlled type 2 diabetes.
- Emerging utility of once-weekly exenatide in patients with type 2 diabetes.
- Protocol for a randomised, double-blinded, controlled trial of youth with childhood-onset obesity treated with semaglutide 2.4 mg/week: the RESETTLE trial.
- Glucagon-like Peptide-1 receptor agonists for the prevention and treatment of Parkinson's disease.
- Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetes.
- The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis.
- Utilization Trends of Dual GIP/GLP-1 Receptor Agonist, Newer Glucose-Lowering Medications, and Anti-Obesity Medications Among Patients With Chronic Kidney Disease With and Without Type 2 Diabetes.
- Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies.
- Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide.
- [Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide].
- Once-Weekly Semaglutide in Adolescents with Obesity.
- Case Report: Small Bowel Obstruction After Starting Tirzepatide (Mounjaro).
- Weighing in on glucagon-like peptide-1 receptor agonists in dermatology.
- Pre-stroke weight loss by glucagon-like peptide 1 receptor and neuropeptide Y receptor Y2 activation improves post-stroke functional recovery in male diabetic mouse models.
- Real-World Use of Once-Weekly Semaglutide in Thai Patients With Type 2 Diabetes Mellitus in a Private Hospital Setting.
- Glucagon-Like Peptide-1 Receptor Agonists During Electroconvulsive Therapy: Case Report With Evolving Concerns and Management Considerations.
- Six Substudies From the Semaglutide Trials: Identifying Mechanisms of Benefit and Whom to Treat.
- Noninvasive quantitative evaluation of viable islet grafts using <sup>111</sup> In-exendin-4 SPECT/CT.
- A meta-analytic review of the safety and efficacy of semaglutide in type 2 diabetes mellitus and chronic kidney disease patients.
- Lanifibranor and semaglutide demonstrate multiple metabolic benefits in free-choice diet induced obese hamster models of MASH and MetALD.
- An Introduction to Tirzepatide.
- Acute Exenatide Therapy Attenuates Postprandial Vasodilation in Humans with Prediabetes: A Randomized Controlled Trial.
- Oleic acid and glucose regulate glucagon-like peptide 1 receptor expression in a rat pancreatic ductal cell line.
- Developing a novel exenatide-based incretin mimic (αB-Ex): Expression, purification and structural-functional characterization.
- Ultra-high-performance liquid chromatography for the determination of exenatide in monkey plasma by tandem quadrupole mass spectrometry.
- Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach.
- Combined Insulin and GLP-1 Receptor Agonists: Simplifying Treatment or Adding Obstacles?
- [Injection of submandibular gland with recombinant Exendin-4 and adeno-associated virus for the treatment of diabetic rats].
- Exenatide administration time-dependently affects the hepatic circadian clock through glucagon-like peptide-1 receptors in the central nervous system.
- Silk fibroin hollow microneedle system for sustained transdermal administration of liraglutide: development and characterization.
- A single dose of exenatide had no effect on blood flow velocity in the middle cerebral artery in elderly healthy volunteers: Randomized, placebo-controlled, double-blind clinical trial.
- Tirzepatide and kidney function: an intriguing and promising observation.
- Tirzepatide for Heart Failure and Obesity. Reply.
- Clinical Efficacy and Safety of Liraglutide and Dapagliflozin on Glucose and Lipid Metabolism and Insulin Function in Patients with Type 2 Diabetes Mellitus.
- Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies.
- Effects of GLP-1 receptor agonists on copeptin in euvolemic participants.